PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating)'s stock price traded up 0.4% during trading on Tuesday . The stock traded as high as $2.88 and last traded at $2.84. 33,197 shares changed hands during mid-day trading, an increase of 276% from the average session volume of 8,831 shares. The stock had previously closed at $2.83.
PharmaCyte Biotech Price Performance
The company's 50 day simple moving average is $2.94 and its 200 day simple moving average is $2.86.
PharmaCyte Biotech Company Profile
(Get Rating)
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Featured Articles
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.